- Investing.com
Metrics to compare | PASG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPASGPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.4x | −5.2x | −0.4x | |
PEG Ratio | −0.01 | −0.06 | 0.00 | |
Price/Book | 3.4x | 2.1x | 2.6x | |
Price / LTM Sales | - | 46.1x | 3.1x | |
Upside (Analyst Target) | 255.5% | 125.3% | 47.5% | |
Fair Value Upside | Unlock | −6.7% | 5.9% | Unlock |
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington’s disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania’s Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.